Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of RPH-001 vs Avastin in Healthy Volunteers
NCT03659305Phase 1Completed
- Sponsor
- R-Pharm
- Start
- Jul 2018
- Primary completion
- Jan 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of RPH-001 in colorectal cancer (metastatic) (mCRC), Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), renal cell carcinoma (RCC) and 4 more (2 arms), sponsored by R-Pharm. Primary endpoints: Maximum Plasma Concentration (Cmax) up to 2376 hours, Area Under the Curve from Time Zero to Last Quantifiable Concentration (AUC(0-t)) up to 2376 hours and 1 more. Started Jul 2018; status: completed.
02
Drugs
RPH-001
03
Conditions
colorectal cancer (metastatic) (mCRC)Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)renal cell carcinoma (RCC)glioblastoma (GBM)ovarian cancer
Beyond the preview
Go deeper on NCT03659305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03659305.